IL17A and skin disorder: Furthermore, we employed blockade of IL-17A signaling using an anti-IL-17A neutralizing monoclonal antibody in order to compare the effect with anti-IL-6R antibody on IMQ-induced psoriasis-like dermatitis in PD-1−/− mice.